RxDoctor Payments Data

Arshed Malik, MD

Interventional Cardiology · Metairie, LANPI 1487659595

Payments from drug & device makers

$6,726in general payments, 2019–2025

Across 400 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$885
  • Pfizer$875
  • E.r. Squibb & Sons, L.L.C.$635
  • Boehringer Ingelheim$355
  • Amgen$348
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$6,66199%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,726 in reported general payments places this provider in the 35th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$148,248
Medicare patients
1,015
Services billed
2,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban680$681,058
XareltoRivaroxaban222$225,115
EntrestoSacubitril/Valsartan178$190,909
Repatha SureclickEvolocumab71$82,057
MultaqDronedarone Hcl29$43,430
JardianceEmpagliflozin65$39,809
BrilintaTicagrelor28$25,108
FarxigaDapagliflozin Propanediol20$22,369
VascepaIcosapent Ethyl27$11,102
Metoprolol Succinate613$6,948
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,323
Atorvastatin Calcium645$5,224
ClopidogrelClopidogrel Bisulfate306$3,120
Rosuvastatin Calcium233$2,918
Losartan Potassium369$2,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$875$681,058680 claims
Johnson & JohnsonXarelto$1,202$225,115222 claims
NovartisEntresto$885$190,909178 claims
AstraZenecaBrilinta, Farxiga$166$47,47748 claims
Sanofi-aventis U.S. LLCMultaq$280$43,43029 claims
Boehringer IngelheimJardiance$355$39,80965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →